Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Extends Offer for Dionex

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market Tuesday that it has extended until midnight, New York City time, on April 7, its tender offer to acquire all of the outstanding shares of Dionex.

Thermo Fisher inked the deal in December to acquire Dionex for $118.50 per share in cash for a total transaction value of $2.1 billion. The tender offer represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

As of 5:00 pm, New York City time, on Feb. 15, approximately 9.1 million shares of Dionex's common stock, representing around 52 percent of all outstanding shares, had been tendered and not withdrawn from the offer.

The deal already has cleared US antitrust review, and Thermo Fisher expects to close the deal early in the second quarter, it said yesterday.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.